Oncolytics Biotech Reports 2021 First Quarter Development Highlights and Financial Results
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep s anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical studies show that pelareorep s synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors
- Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021
- Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022
SAN DIEGO and CALGARY, AB, May 7, 2021 /PRNewswire/ Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended March 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.
Operator
Good day ladies and gentlemen and welcome to Oncternal s Therapeutics Inc. first-quarter 2021 financial results call. [Operator instructions] At this time it is my pleasure to turn the floor over to your host Richard Vincent. Sir the floor is yours.
Rich Vincent
Chief Financial Officer
Thank you, Melinda. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon are our president and CEO, Dr. James Breitmeyer; and our acting CMO, Dr.
Edwina Baskin-Bey. We welcome all of you. Today s call includes a business update and discussion of our 2021 first-quarter financial results which will be followed by Q&A. Today s press release and replay of today s earnings call will be available on the Investor Relations section of Oncternal s website for at least the next 30 days.
Bicycle Therapeutics plc: Bicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
BT7480, the lead Bicycle
tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 New Drugs on the Horizon session; remains on-track for 2H 21 clinical trial start
Achieved significant recent progress across pipeline of Bicycle
-based therapies beyond oncology
Raised $75.0 million through at-the-market offering program; cash of $195.9 million as of March 31, 2021 expected to provide financial runway through multiple clinical milestones and into 2024
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle) technology, today reported financial results for the first quarter ended March 31, 2021 and discussed recent corporate updates.
Merus N.V.: Merus Announces Financial Results for the First Quarter and Provides Business Update
MCLA-145 clinical update planned for 2H21
MCLA-129 first patient dosed in phase 1/2 trial
Cecile Geuijen, Ph.D., promoted to Chief Scientific Officer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS) ( Merus , the Company, we , or our ), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics
), today announced financial results for the first quarter that ended March 31, 2021, and provided a business update. We have made significant progress on our clinical programs this quarter and we are excited to provide a clinical data update on Zeno in an oral presentation at ASCO in June, and on MCLA-145 later this year, said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. In addition we continue to validate our multispecific platforms with our re
Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end
RUBY trial of EDIT-301 for sickle cell disease active and recruiting
Preclinical ocular data presented at ARVO supports in vivo gene editing
$723 million
as of March 31, 2021
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021.
“Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage medicines,” said James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine. “We are pleased to announce Dr. Mark Shearman will be joining Editas as Chief Scientific Officer in June 2021. Mark has an outstanding track record of drug discovery and development, and we are confident that